➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
AstraZeneca
McKesson
Harvard Business School
Express Scripts

Last Updated: July 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,006,224


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,006,224 protect, and when does it expire?

Patent 9,006,224 protects AFINITOR and is included in one NDA.

This patent has forty-eight patent family members in twenty-four countries.

Summary for Patent: 9,006,224
Title:Neuroendocrine tumor treatment
Abstract: A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.
Inventor(s): Marks; Peter Wayne (Woodbridge, CT), Lebwohl; David (Madison, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:12/094,173
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,006,224
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,006,224

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis AFINITOR everolimus TABLET;ORAL 022334-003 Jul 9, 2010 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC ⤷  Free Forever Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-001 Mar 30, 2009 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC ⤷  Free Forever Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-004 Mar 30, 2012 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC ⤷  Free Forever Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-002 Mar 30, 2009 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,006,224

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0523658.3Nov 21, 2005
United Kingdom0601082.1Jan 19, 2006
United Kingdom0602747.8Feb 10, 2006
United Kingdom0607942.0Apr 21, 2006
PCT Information
PCT FiledNovember 20, 2006PCT Application Number:PCT/EP2006/068656
PCT Publication Date:May 24, 2007PCT Publication Number: WO2007/057457

International Family Members for US Patent 9,006,224

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006314444 ⤷  Free Forever Trial
Australia 2010202866 ⤷  Free Forever Trial
Brazil PI0618808 ⤷  Free Forever Trial
Canada 2629245 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Johnson and Johnson
AstraZeneca
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.